Royalty Pharma Shares Under Pressure as Novartis' Pelacarsen Phase 3 HORIZON Trial Disappoints
RPRX's royalty stake in pelacarsen suffers as Novartis' Phase 3 cardiovascular outcomes trial misses key endpoints, pressuring net present value of fu…
Merck and Moderna's mRNA Cancer Vaccine Scores Phase 3 Win — What It Means for MRK and MRNA Investors
The Phase 3 INTerpath-001 trial of Moderna's personalized mRNA cancer vaccine plus Merck's Keytruda met both co-primary endpoints in high-risk melanom…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
August Jobs Report Fuels Fed Rate-Hike Speculation: What It Means for Investors
The August jobs report stirs Fed rate-hike speculation, impacting Treasury yields and equity valuations, particularly fo…
SoundHound AI's Acquisition of LivePerson: Implications for the Tech Market
Analyzing SoundHound AI's acquisition of LivePerson and its impact on the conversational AI landscape.
Moderna and Merck's mRNA Cancer Vaccine Trial: A Turning Point for Biotech Investors
The Phase 3 INTerpath-001 trial results could reshape oncology market dynamics for Moderna and Merck, opening new revenu…
Record Diesel Prices Raise Inflation Concerns in North American Markets
Soaring diesel prices driven by geopolitical conflicts are stirring inflation fears across North America, impacting mult…
Merck and Moderna's mRNA Vaccine Triumphs in Melanoma Phase 3 Trials
Merck and Moderna's Phase 3 trial results demonstrate significant advancements in melanoma treatment, impacting stock pe…
Ionis Pharmaceuticals Secures FDA Approval for Groundbreaking Zanvastro Treatment
Ionis Pharmaceuticals' Zanvastro receives FDA approval, marking a significant milestone in the treatment of Alexander di…
PayPal's Stock Rises Amid Takeover Speculation: What Investors Should Know
PayPal's stock is seeing upward movement amid takeover talks, fueled by a strong ISM Non-Manufacturing PMI report. Here'…
AbbVie Expands Immunology Pipeline with $11 Billion Acquisition of Apogee Therapeutics
AbbVie makes a bold move, acquiring Apogee Therapeutics for $11 billion, signaling a strategic push in immunology.
Moderna's 177% Surge: The Successful Phase 3 Trial That Could Transform Oncology
Moderna's recent Phase 3 trial success has triggered a 177% stock surge, signaling a potential new era in oncology inves…